Provectus Pharma (OP: PVCT )

0.1931 +0.0018 (+0.94%)

Streaming Delayed Price Updated: 3:59 PM EDT, May 3, 2024 Add to My Watchlist

Price and Volume

Volume	128,865
Open	0.1980
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.1913
Today's Range	0.1901 - 0.1980
52wk Range	0.0560 - 0.2245
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

PVCT Stock Earnings: Provectus Reported Results for Q4 2023

March 28, 2024

Provectus just reported results for the fourth quarter of 2023.

Via InvestorPlace

Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December

January 17, 2023

On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate...

Via Benzinga

Performance

YTD	+84.26%	+84.26%
1 Month	+20.76%	+20.76%
3 Month	+49.23%	+49.23%
6 Month	+77.16%	+77.16%
1 Year	+41.88%	+41.88%

More News

Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023

December 12, 2022

From Provectus Biopharmaceuticals Inc.

Via GlobeNewswire

Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022

December 01, 2022

From Provectus Biopharmaceuticals Inc.

Via GlobeNewswire

Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022

November 10, 2022

From Provectus Biopharmaceuticals Inc.

Via GlobeNewswire

Provectus Biopharmaceuticals Announces World Health Organization Selection of “Rose Bengal Sodium” as International Nonproprietary Name for Active Pharmaceutical Ingredient

November 02, 2022

From Provectus Biopharmaceuticals Inc.

Via GlobeNewswire

Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation

October 25, 2022

From Provectus Biopharmaceuticals Inc.

Via GlobeNewswire

Provectus Biopharmaceuticals Establishes Research Collaboration with University of Texas Medical Branch at Galveston to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal for Wound Healing

September 29, 2022

From Provectus Biopharmaceuticals Inc.

Via GlobeNewswire

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.